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A PARADIGM SHIFT IN THE DIAGNOSIS AND TREATMENT OF POLYCYSTIC 
OVARIAN SYNDROME: A PRACTICE CHANGE IN PRIMARY CARE 
 
 
An Abstract of the Scholarly Project by 
Patricia Lynn Sullivan 
 
 
The purpose of this DNP Scholarly Project was to determine whether participants’ 
knowledge of the updated guidelines on the diagnosis and treatment of the obese patient 
with polycystic ovarian syndrome (PCOS) is increased following a continuing education 
presentation.  The increase in the knowledge of PCOS guidelines for an obese patient is 
documented using a pretest/ posttest method following the continuing education program 
which utilizes a PowerPoint presentation.  Polycystic ovarian syndrome (PCOS) is the 
most common endocrine disorder in women.   This Doctor of Nursing Practice (DNP) 
capstone project was designed to provide a literature review and best practice guidelines 
delivered through the use of an educational PowerPoint presentation for the purpose of 
educating nurse practitioners and nurse practitioner students on the inflammatory 
complexity of a PCOS diagnosis. A portion of the presentation discussed the role of FDA 
approved liraglutide in the treatment of obese women with a co-morbidity of PCOS. A 
quasi-experimental one-group pretest/posttest design instrument in the form of an index 
was created for this study.  The index included four dimensions with four questions each.  
The dimensions involved the four research questions for this project.  The sample of 
convenience included 16 nurse practitioners and 2 nurse practitioner students. The results 
did provide data that a learning curve exists by analyzing the pretest and posttest scores 
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for the PowerPoint presentation.  This study did reflect the need for increased education 
in nurse practitioners to more appropriately diagnose and treat the obese PCOS patient. 
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“For us who nurse, our nursing is a thing which, unless we are making 
 progress in nursing every year, every month, every week,  
take my word for it, we are going back”,  




Polycystic Ovarian Syndrome (PCOS) is the most common endocrine disease 
affecting women of childbearing age (Roe & Dokras, 2011). The Department of Health 
and Human Services (DHHS) reports there are more than 5 million women suffering 
from Polycystic Ovarian Syndrome currently (2014).  According to a recent study 
published in the Endocrine Society’s March 2015 issue of Journal of Clinical 
Endocrinology & Metabolism, women diagnosed with PCOS are twice as likely to be 
hospitalized for heart disease, diabetes, mental-health conditions, reproductive disorders’, 
and cancer of the uterine lining due to an underlying inflammatory etiology.  The cost of 
evaluating and providing care to women with PCOS is approximately $4.36 billion per 
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year (Hart & Dorghty, 2015).  Similar inflammatory correlations have been identified in 
obesity and PCOS (Gonzalez, Sia, Shepard, Rote, & Minium, 2014). 
The National Center for Health Statistics reported in 2013 that an approximate 68 
percent of Americans over the age of 18 are overweight or obese.  In the past, obesity 
was merely looked upon as a caloric matter versus hormonal and inflammatory causes 
(NCHS, 2013).  In 2013, the American Medical Association (AMA) addressed this 
symptom of obesity and finally categorized it for the first time as a chronic disease state 
involving gut hormone inflammatory dysregulation rather than a mere symptom (AMA, 
2013). 
Treatment options for obesity in the PCOS patient are limited.  These limitations 
include the complexity of the disorder, an unknown etiology, and lack of financial 
backing for research (NIH, 2012). Both metabolic and reproductive abnormalities are 
amplified in PCOS similar to the obese patient (Franks, 2011).  In turn, obesity in the 
PCOS patient exacerbates objective and subjective findings due to an increase in insulin 
resistance, androgens, and inflammatory markers. These findings are already elevated at 
baseline in PCOS, independent of a co-morbidity of obesity (Gonzalez, 2015).  Adipose 
tissue becomes a catalyst to PCOS (2015). 
Genetic and epigenetic influences are linked to PCOS (Gonzalez, 2015).  It is likely 
that epigenetics is more of a facilitator to the disease rather than solely from genetic 
inheritance (Franks et al., 1997).  In the research, evidence based findings report dietary 
habits such as increase glucose adds to the epigenetic expressions.  Recent findings in the 
study of PCOS report that metabolic deviations and ovarian dysregulation are caused by 
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insulin resistance and inflammation (Gonzalez, 2015).  This is the linkage which 
associates the obese patient without PCOS and the effects of an increase in adipose tissue 
enhancing insulin resistance and inflammation. 
Identifying and treating PCOS is ambiguous among many health care 
professionals (NIH, 2012).  This is due to the similarities of objective and subjective 
findings in other endocrine disorders (Boyle & Teede, 2011). Current PCOS guidelines 
recommend lifestyle changes in caloric intake and exercise for weight loss. No 
medication recommendation is offered (Endocrine Society, 2013).  Research finds 
lifestyle modifications have limited outcomes in PCOS with weight loss (2013). New 
obesity guidelines offer a novel treatment for weight loss in PCOS which also impedes 
inflammatory markers.  These inflammatory markers are key in exacerbation of the 
disease process (AACE/ACE, 2016). This therapy contradicts the previous guidelines 
from the Endocrine Society on weight loss in the PCOS patient. 
 In December 2012, a PCOS workshop was sponsored by the Office of Disease 
Prevention and the Eunice Kennedy Shriver National Institute of Child Health and 
Human Development through the NIH.  Invited experts came together to discuss 
independent and unbiased evidence to facilitate discussion.  An executive summary 
indicated for most of the twentieth century PCOS has been a poorly understood 
condition.  Also, the distractive title limited the assumptions of the disease to an isolated 
gynecological state.  It also allowed for an underdevelopment in education for clinicians 
and need for funded research in discovery of the metabolic causes and pathologies of the 
disease state (NIH, 2012).  
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In a final position paper written by the NIH selected committee, they 
recommended a change in the name of the disorder.  The name change would further 
reflect the complex inflammatory, metabolic, hypothalamic, pituitary, ovarian and 
adrenal interactions which characterize this disease state. The experts also recommended 
future translational research on mechanisms which alter the hormone functions. This 
would allow for the establishment of models to be developed in identifying innovative 
therapies for the treatment of PCOS due to the underlying inflammatory and metabolic 
components with PCOS (NIH, 2012).  
At the American Diabetes Association Scientific Conference June, 2016, an 
Australian Endocrinologist presented a lecture entitled, “Clinical Update and 
Implications – Renaming PCOS.”   The changed name to be considered is “Metabolic 
Reproductive Syndrome” (Teede, 2016).   
The purpose of this research is to disseminate updated knowledge and correlations 
between inflammatory and metabolic dysregulation research findings with PCOS. The 
more interesting aspect is to strongly support a paradigm shift in treatment of the obese 
patient with a co-morbidity of PCOS. Documented antiquated guidelines are causing 
missed diagnosis and sub-therapeutic treatment options for this misunderstood population 
(NIH, 2012).  In turn, research allows for opportunities to increase future funded research 
for metabolic treatments despite the BMI.  This syndrome deserves further exploration in 
order to find a cause. 
Description of the Need for Clinical Practice Guidelines 
 In 2013, The Endocrine Society appointed a Task Force of experts to formulate 
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 practice guidelines for the diagnosis and treatment of PCOS.  The Clinical Guide 
Subcommittee deemed the diagnosis and treatment of PCOS a priority area in need of 
practice guidelines (p. 4570).  Primary and secondary causes along with correct diagnosis 
is imperative for treatment options (Jensterle, Kocjan, Pfeifer, Kravos, & Janez, 2010; 
NIH, 2012).  Implementing this guideline of recommendations assists in an appropriate 
diagnosis consistent with evidence in order to treat appropriately each patient based on 
the diagnosis and co-morbidities. These guidelines are aimed at helping physicians and 
patients understand a complex condition which often has diverse symptoms (2013).   
Inflammation is hallmark in the pathophysiology of PCOS (Gonzalez, 2011). The 
effect of inflammatory markers like Tumor Necrosis Factor-alpha (TNF-α), among others 
are responsible for these symptoms and co-morbidities.  Similarities of increased 
inflammatory markers are seen between obesity alone and the obese, PCOS patients 
(Gonzalez, Sia, Shepard, Rote, & Minium, 2014).  A further discovery from the research 
is an elevation in these inflammatory markers being responsible in part for the decreased 
expression of a gut hormone, GLP-1, from the L cells in the small intestine.  Decreased 
GLP-1 is associated with insulin resistance which further increases adipose production 
(Gonzalez, 2013).  For us who nurse, our nursing is a thing which, unless we are making 
progress every year, every month, every week, take my word for it, we are going back 
(Nightingale, 1872) 
GLP-1 agonists, like liraglutide, are a class of medications that allow for insulin-
glucose homeostasis by promoting insulin secretion and limiting glycogen release 
(Franks, 2011). GLP-1 levels in PCOS patients were found to be significantly lower 
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when compared to healthy women (Wang, Liu, Chen, Li & Qu, 2015). GLP-1 
medications are often misrepresented as an insulin sensitizer because of the improved 
glucose and loss of adipose tissue results with the medication.  This medication has been 
proven to assist in weight loss for patients with Type II Diabetes (T2DM) (Franks, 2011).  
Early GLP-1 therapy may preserve pancreatic beta cell function in subjects with Impaired 
Glucose Tolerance (IGT) and PCOS by reducing TNF-α.  GLP-1 agonists have been 
FDA approved for obesity (Whitten, 2016).  This allows for the FDA approval to 
prescribe liraglutide for obesity despite other co-morbidities (AACE/ACE, 2016). 
The purpose of this research includes delineation of the inflammatory 
pathophysiology of obesity and similarities to the obese PCOS patient. This links these 
correlations with a treatment option through these guidelines.  This therapeutic option 
improves many outcomes of the disease.  These outcomes involve an ability to decrease 
key inflammatory markers and weight in these women in order to improve hormone 
levels which complicate the symptoms of PCOS. 
Significance to Nursing and the Role of the Family Nurse Practitioner 
Nursing as a profession continues to evolve from its inception.  Florence 
Nightingale was the change agent of her time, moving the nursing concept from a 
vocation to a profession (Ulrich, 1992).  A famous quote from her is, “Unless we are 
making progress in nursing every year, every month, every week, take my word for it, we 
are going back” (Ulrich, 1992).  Discussions across the United States in Doctoral nursing 
programs are focused on the current paradigm shift this profession is facing in the fluidity 
of current healthcare challenges (Sullivan, 2013).  The need for clinical based nursing as 
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clinicians, researchers, and scientists is at the forefront as the DNP gains leadership in the 
healthcare community (2013).  The significance to nursing parallels Florence Nightingale 
on the challenge to evolve. 
A paradigm shift in 2013 classifying obesity as a disease rather a than symptom 
allows nursing the ability to treat obese patients the same as treating hypertension, 
diabetes, and all other disease states (AMA, 2013).  This permits a new level of care and 
therapeutic treatment options gradually being covered by insurance companies for the 
overweight and obese patient population. Along with obesity, treatment guidelines 
established for PCOS potentially expedites the diagnosis and treatment to allow for a 
decrease in potential chronic co-morbidities that are associated with PCOS (NIH, 2012 )  
Specific Aims/Purpose 
This research accomplishes the following DNP essentials in disseminating the 
paradigm shift in the diagnosis and treatment of PCOS by: 1) completing an exhaustive 
literature review integrating the link between liraglutide, inflammatory marker 
similarities in obesity and PCOS, improvement of hormone levels, and weight reduction 
as treatment for obese patients with PCOS; 2) Developing an educational PowerPoint 
with  one CE credit hour through American Academy of Nurse Practitioners (AANP)  
regarding obese patients with PCOS for providers. Along with this, updated practice 
guidelines for the diagnosis and treatment of PCOS; 3) conducting a pretest and posttest 
for the continuing education program; and 4) summarize the impact of the project on 
practice and recommendations for future opportunities.  
Theoretical Framework  
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Albert Einstein was quoted  
“… creating a new theory is not like destroying an old barn and erecting a 
skyscraper in its place. It is rather like climbing a mountain, gaining new 
and wider views, discovering un-expected connections between our 
starting point and its rich environment. But the point from which we 
started out still exists and can be seen, although it appears smaller and 
forms a tiny part of our broad view gained by the mastery of the obstacles 
on our adventurous way up” (Einstein, 1938).  
Chaos Theory 
Conceptual shifts are occurring in many areas of healthcare and medicine based on 
the premises of the chaos theory (Hoffman, 2000).  Complexity science utilizes the Chaos 
theory to expand on knowledge rather than discovering new knowledge (2000). 
The chaos theory summarizes the undertones of order in a state of total 
disorganization hammering the healthcare system in the United States currently.  Chaos 
Theory frames the understanding with nursing in being willing to adjust and being 
malleable in this current paradigm shift with medicine (Grossman & Valiga 2013).  Clark 
(2008) states in her book, Classroom Skills for Nurse Educators, the application of the 
chaos theory for nurse educators helps students during simulations that allows for a 
purpose of uncertainty.  This theory helps students understand the uncertainty of a new 
patient.  At that juncture varied appropriate interventions can be identified and adjusted 
as the simulated patient changes (2008).   
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This is similar to the uncertainty of a patient with PCOS.  Diverse epigenetic 
challenges arise with multiple variables altering the patient’s symptoms and treatments at 
any given time (Gonzalez, 2015). Epigenetic variables include the patient’s diet, lifestyle, 
and environment among other gene altering stimuli (2015).  Treatment algorithms and 
protocols are limited and guideline attempt to force all patients with PCOS into “boxes” 
that may not be appropriate with each unique presentation (NIH, 2012).    
Grossman and Valiga (2013) incorporates a discussion allowing the chaos theory to 
be applied to patient-centeredness, critical thinking, and creativity during this time for 
improved patient outcomes (2013).  The conceptual terms consistent within this 
theoretical framework allow for a comparison applicable to this research.  Definitions of 
concepts in relation to the chaos theory are in the following table.  A second table 
following defines the parallel of these definitions to PCOS. 
Table 1.  Chaos Theory Conceptual Definitions (Oestreicher, 2007) 
Causality Principle Every effect has an antecedent proximate cause. 
Characteristic Lyapynov 
time 
The characteristic time of a system is defined as the delay 
when changes from the initial point are multiplied by 10 in 
a phase space 
Feedback A response to information, that either increases effects 
(positive) or decreases them (negative), or induces a cyclic 
phenomenon 
Determinism A philosophical proposition that every event is physically 
determined by an unbroken chain of prior occurrences 
Predictability This refers to the degree that a correct forecast of a 
system’s state can be made either qualitatively or 
quantitatively. 
Model A patter, plan, representation, or description designed to 
show the structure or workings of an object, system, or 
concept. 
Dynamical system A system that changes over time in both a causal and a 
deterministic manner; i.e, its future depends only on 
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phenomena from its past and its present and each given 
initial condition will lead to only one given later state of the 
System (determinism).  Systems that are noisy or stochastic, 
in the sense of showing randomness, are not dynamical 
Systems, and the probability theory is the one to apply to 
their analysis. 
Phase space An abstract space in which all possible states of a System 
are represented, which, each possible state of the System 
corresponding to one unique point in the phase space. 
Integral System In mathematics, this refers to a System of differential 
equations for which solutions can be found.  In mechanics, 
this refers to a system that is quasiperiodic. 
Linear System A system is said to be linear when the whole is exactly 
equal to the sum of components. 
Attractor A set to which a dynamical System evolves after a long 
enough time. 
Sensitivity to initial 
conditions. 
This is when a change in one variable has the consequence 
of an exponential change in the System. 
          
In reviewing the conceptual terms describing the chaos theory, this research 
identifies a parallel description of the terms as themes. These themes resonate through the 
PCOS disease state and symptomology of the females with this disorder.  The purpose of 
this research is to focus on the obese PCOS patient and inflammatory marker elevations. 
These elevations could potentially have devastating outcomes if not harnessed. The 
diversity of the symptoms and treatments depend on genetic and epigenetic factors 
influencing a multitude of cause and affect exchanges with each patient (Gonzalez, 
2015). In the following diagram correlations are identified with the conceptual definitions 
paralleling this research. 
Definition of Terms: 
 This section describes the definitions for the terms utilized in this study: 
Polycystic Ovarian Syndrome – A condition in some women of abnormal hormone levels 
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Table 2.  PCOS Conceptual Definitions in Relation to the Chaos Theory 
Causality Principle Elevated inflammatory markers, GLP-1 and adiponectin 
abnormality, insulin resistance. 
Characteristic Lyapynov 
time 
The time a patient with PCOS increases adipose tissue 
causing worsening of symptoms from the initial symptoms. 
Feedback Increased Inflammatory markers, worsening insulin 
resistance, elevated androgens, obesity, infertility, acne, 
excessive body hair, male pattern hair loss, diabetes, etc. 
Determinism Polycystic Ovarian Syndrome 
Predictability Hypothesis of elevation of adipose tissue and the symptoms 
of PCOS in obese females. 
Model Adipose tissue 
Dynamical system Hormonal changes that are consistent with the probability 
of a diagnosis of PCOS 
Phase space An abstract space in which all possible presentation of an 
obese patient with PCOS is represented which, each 
possible presentation of the symptoms correspond to one 
unique point in the parameters of this space. 
Integral System Domino effect of dysregulation of female hormones 
secondary to inflammatory markers from an increase in 
adipose tissue. 
Linear System The perfect hormone regulation that does not deviate from 
normal 
Attractor Elevated inflammatory markers, Insulin resistance, 
Amenorrhea, Ovarian Follicles. 
Sensitivity to initial 
conditions. 
Elevated inflammatory markers, Insulin resistance, 
Polycystic Ovarian Syndrome, hypertension, diabetes, 
vasculopathies, infertility. 
 
resulting in irregular menstruation, hirsutism, acne, ovarian cyst, and infertility.  
Treatment involves weight loss and hormones (Sell, Rothenburg, & Chapman, 2012) 
Liraglutide is marketed under the trademark Victoza© and Saxenda© (Whitten, 2016). 
TNF-α – is directly proportional to fat mass and has been shown to be involved in the 
development of insulin resistance.  It decreases insulin receptors and down-regulates 
several steps in the insulin-signaling pathway.  It is a protein which is produced chiefly 
by monocytes and macrophages in response to endotoxins that mediate inflammation.  It 
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is an inhibitor of insulin on the insulin receptor increasing insulin resistance.  This is 
elevated in PCOS and worsens insulin resistance, GLP-1 resistance, and GLP-1 
production (Gagnon et. al., 2015) 
Insulin resistance – A reduction to the sensitivity of insulin by the body’s insulin-
dependent processes such as glucose uptake and lipolysis (Franks, 2011). 
Epigenetics - Epigenetics describe the alterations of gene expression despite any 
alterations to the genetic sequence (Chuang & Jones, 2007) 
GLP-1 – one of two intestinal hormones secreted when nutrients such as carbohydrates 
and lipids are present in the small intestine. It stimulates the release of insulin from 
pancreatic beta cells in conjunction with carbohydrates that are absorbed from the gut 
while inhibiting glucagon secretion, stomach emptying and food intake. It regulates 
postprandial glucose homeostasis.  PCOS hormone dysregulation involves a decreased 
production and sensitivity of GLP-1 which leads to worsening symptoms of the disease. 
Body mass index (BMI) – A useful tool to calculate body fat.  It is a measurement of 
weight (kilograms) divided by the height (meters) (Institute for Clinical Systems 
Improvement, 2013). It is useful to correlate with coexisting health problems (2013). 
Clinical Practice Guidelines – Reports which include recommendations for improving 
patient care and outcomes through disseminating a systematic review of evidence and an 






 PCOS is the number one endocrine disorder in women.  Coupled with obesity, 
inflammation worsens the disease process.  Many studies have looked at the long term 
effects of the obese PCOS patient.  New guidelines were implemented in May, 2016 for 
obesity associated with PCOS and in 2013 for PCOS. Nurse practitioners in the primary 
care setting must be educated on to appropriate diagnosis and treatment of PCOS.  
Chapter II presents a literature review on the updated guidelines as well as multiple 
research studies utilizing medication to treat the obese PCOS patient.  It goes on to 


















This chapter discusses research and guidelines on the diagnosis and management 
of PCOS with a focus on the obese PCOS patient.   The purpose of this research is to 
disseminate imperative knowledge to support a paradigm shift in the diagnosis and 
treatment of PCOS with obesity. This is achieved by blending current evidence based 
guidelines for PCOS and Obesity along with supportive research studies reinforcing 
novel trends in pathophysiology and treatment. 
The review of literature is achieved through multiple online databases.  The 
research is generally limited to the last five years. Due to the diagnosis classification 
being a rare disease, some research exceeds the five year mark to allow the reader full 
bodied research from the inception of the diagnosis. 
The phrases being used for search includes “PCOS,” “obesity,”  “GLP-1 agonists 
and obesity,” “Clinical practice guidelines in PCOS” and “inflammatory markers with 
PCOS”. The statistical information from the website of the Centers for Disease Control 
and Prevention and the National Institutes of Health are reviewed. In searching these 
different words and phrases, there are over 30 peer-reviewed articles with information 
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being utilized for this scholarly project. The following categories distinctly satisfy a 
portion of necessary essentials for the DNP program.  The first category is a literature 
review correlating obesity, PCOS, inflammatory markers, and lirglutide. The second 
category involves developing a one hour CE, through AANP, Power Point presentation. 
A pretest and posttest comparison involving area nurse practitioners and nurse 
practitioner students is conducted.  The CE includes the pathophysiology, diagnosis, and 
treatment of obesity in the PCOS patient.  The third category is further dissemination of 
the information from this research in future state and national conferences. This allows 
for updated practice changes in the primary care setting to be the rule and not the 
exception in treating PCOS. 
Practice Change Guidelines 
The Endocrine Society 2013 guidelines, Diagnosis and Treatment of Polycystic 
Ovarian Syndrome:  An Endocrine Society Clinical Practice Guideline,” recommends 
three primary recommendations which delineate into 32 more precise recommendations 
for the diagnosis, co-morbidities, and treatment of PCOS.  The Endocrine Society 
appoints a Task Force of experts to formulate practice guidelines for the diagnosis and 
treatment of PCOS.  The Clinical Guide Subcommittee deems the diagnosis and 
treatment of PCOS a priority area in need of practice guidelines (p. 4570).  Primary and 
secondary causes along with correct diagnosis is imperative for the correct treatment of 
PCOS (Jensterle, Kocjan, Pfeifer, Kravos, & Janez, 2010). 
Implementing this guideline and bundle of recommendations is to individually 
diagnose appropriately each patient according to the severity of the disease and co-
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morbidities. These guidelines are aimed at helping physicians and patients understand a 
complex condition that often has diverse symptoms (2013).  PCOS continues to be 
underdiagnosed in adolescents and adults due to the complexity and diverse subjective 
and objective findings (March et. Al., 2012). 
Under diagnosis of PCOS is concerning due to the long term reproductive health 
consequences and associated cardio metabolic risks. These women have increased risk of 
metabolic syndrome, diabetes, heart disease, and death (Coviello, Legro & Dunaif, 2006).  
Due to this, assessing and establishing the diagnosis is important for further counseling 
and treatment. 
Three evidenced based diagnostic criteria protocols have been available but tend 
to be under-utilized by healthcare providers and medical professions currently.  This is 
due to variations and confusion among the different specialties involved in treating PCOS 
(Bonny et. Al., 2012). These protocols include the NIH 1990, Rotterdam 2003, and 
Androgen and Endocrine (AE)-PCOS Society 2006.  The following tables will identify 
key criteria for each protocol. 
Table 3.  Guidelines for the Diagnosis of PCOS 
NIH 1990 Rotterdam 2003 AE-PCOS Society 2006 
Chronic anovulation 
Clinical and/or biochemical 
signs of Hyperandrogenism 
(with exclusion of other 
etiologies, e.g., congenital 
Oligo-and/or anovulation 
Clinical and/or biochemical 
signs of Hyperandrogenism 
Polycystic ovaries 
(Two of three criteria 
Clinical and/or biochemical 









(Both criteria needed) 
 
Practice Change Recommendations for Implementation 
The Endocrine Society published updated recommendations for PCOS in 2013. 
Obesity is addressed.  Treatment options for the obese PCOS patient in the guidelines.  
These guidelines are limited and state that benefits to the patients are uncertain in 
improving PCOS symptoms (Endocrine Society, 2013). Research clearly identifies that 
weight loss decreases inflammatory markers in patients with PCOS (Gonzales, 2015).   
In 2016, the American Association of Clinical Endocrinologists (AACE) and American 
College of Endocrinology (ACE) introduced updated clinical practice guidelines for 
comprehensive medical care of patients with obesity.  PCOS is listed as a co-morbidity of 
obesity and offers liraglutide as a treatment option for PCOS (AACE, 2016). The 
Endocrine Society in 2013 offered no medication as a treatment for obesity in the PCOS 
patient (2013). 
Diagnosing and Treating PCOS, the Endocrine Society recommendations contain 
three primary recommendations with a total of 32 separate detailed recommendations 
divided within the three primary guidelines. The delineation of these being outlined (See 
Table 4).  The highlighted guidelines are the focus of this research. 
Table 4.  Endocrine Society Practice Change Guidelines 
1.0  Diagnosis of PCOS 1.1 Diagnosis Criteria 
1.2 Diagnosis Criteria for adolescents 
1.3 Diagnosis Criteria for perimenopause 




2.0  Associated morbidity and evaluation 2.1  Documented cutaneous manifestations 
2.2  Screening ovulatory status 
2.3  Exclusion of other causes of  if 
infertility 
2.4  Preconception assessment of BMI, 
B.P., and OGTT 
2.5  No intervention for prevention of 
PCOS in offspring 
2.6  Against routine ultrasound screening 
for endothelial strip 
2.7  Screening PCOS females for 
adiposity by BMI and waist 
circumference 
2.8  Screening for Depression 
2.9  Screen for Obstructive Sleep Apnea 
2.10  Awareness of Fatty Liver Disease, 
but no screening 
2.11 Recommend OGTT to screen for 
glucose intolerance and type II diabetes 
2.12 Screening for CVD  
3.0  Treatment 3.1  Oral Contraceptives as first-line 
management of  PCOS symptoms 
3.2  Screening for contraindications of 
Oral Contraceptives 
3.3  Exercise management in the 
treatment of obesity in PCOS 
3.4  Suggest calorie-restricted diets for 
weight loss in PCOS 
3.5  Suggest against first line therapy for 
treatment of cutaneous manifestations of 
PCOS 
3.6  Recommend metformin in women 
who fail first line therapy for T2DM or 
IGT 
3.7  Recommend clomiphene citrate as 
first-line for infertility 
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3.8  Metformin suggested as an adjuvant 
therapy for infertility to prevent ovarian 
hyper stimulation syndrome in women 
with PCOS undergoing IVF 
3.9  Recommend against use of insulin 
sensitizer such as inositol’s or 
thiazolidineses for treatment of PCOS 
3.10 Recommend against using statins for 
treatment of hyperandrogenism and 
anovulation in PCOS 
3.11 Suggest OCs first line treatment in 
adolescents 
3.12 Premenarcheal girls with advanced 
pubertal development, suggest OC’s 
 
 The 2016 updated obesity guidelines from the AACE/ACE allow for a paradigm 
shift in the treatment of obesity in PCOS.  The guidelines specific for obesity and the co-
morbidity of PCOS state, “What are the weight-related complications that are either 
caused or exacerbated by excess adiposity? (AACE, 2016).  It lists PCOS as one of 15 
co-morbidities of obesity.  Each recommendation is graded according to the strength of 
each recommendation.  Grade A and B indicate a strong or intermediate level of scientific 
substantiation.  The strength of evidence is graded one through four with one being 
strong and four being no clinical evidence (2016).  
Table 5.  2016 AACE Clinical Guidelines for Obesity with Co-Morbidity of PCOS 
(AACE/ACE, 2016) 
Screening for Co-morbidity of Obesity Premenopausal female patients with 
overweight or obesity and/or metabolic 
syndrome should be screened for polycystic 
ovary syndrome by history and physical 
examination; all patients with PCOS should 
be evaluated for the presence of overweight 
or obesity.  (Grade B; BEL 2) 
Treatment: Is weight loss effective to treat R48.  Women with overweight or obesity 
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PCOS?  How much weight loss would be 
required? 
and PCOS should be treated with lifestyle 
therapy with the goal of achieving five 
percent to 15 percent weigh loss or more to 
improve hyperandrogenism, 
oligomenorrhea, anovulation, insulin 
resistance, and hyperlipidemia; clinical 
efficacy can vary among individual patients 
(Grade A; BEL 1)  
R49.  Patients with overweight or obesity 
and PCOS should be considered for 
treatment with orlistat, metformin, or 
liraglutide, alone or in combination, since 
these medications can be effective in 
decreasing weight or improving PCOS 
manifestations including insulin resistance, 
glucose tolerance, dyslipidemia, 
hyperandrogenemia, oligomennorrhea, and 
anovulation (Grade A; BEL 1). 
R50.  Selected patients with obesity and 
PCOS should e considered for laparoscopic 
Roux-en-Y gastric bypass to improve 
symptomatology including restoration of 
menses and ovulation (Grade B; BEL 2) 
Treatment Goals for overweight or obese 
patients with PCOS with BMI> 24: 
Decrease of weight by 5-15 percent 
Ovulation 
Regularization of menses 
Reduced hirsuitism 
Enhanced insulin sensitivity 
Reduced serum androgen levels 
          
 
Implementation Plan 
In an attempt to understanding the disease process of PCOS with obesity, it is 
difficult to have a one size fits all treatment algorithm.  In saying that, a basic evidenced 
template allows for consistency to distinguish a depth of credibility for the diagnosis and 
treatment of PCOS.  Initiating new guidelines in a primary care practice can be difficult 
21 
 
due to the complexity and multiple symptoms of PCOS. Utilizing an implementation 
guideline could facilitate an easier transition in the practice change for PCOS. 
The Registered Nurses’ Association of Ontario (RNAO) environmental scan from 
the Toolkit:  Implementation of Clinical Practice Guidelines (2013) assesses the potential 
readiness of a primary care practice to implement change in PCOS guidelines.  Results of 
the findings are located in Table six that discusses barriers and facilitators. 
Table 6.  Primary Care Practice Readiness to Change in the Treatment of PCOS 
Element Question Facilitators Barriers 
Structure To what extent does 
decision-making 
occur in a 
decentralized 
manner?  Is there 
enough staff to 






level in need of 
specific guidelines 






Workplace Culture To what extent is 
the CPG consistent 
with the values, 
attitudes and beliefs 
of the practice 
environment?  To 
what degree does 
the culture support 
change and value 
evidence? 
The reputation and 
specialty of the 
providers in each 
practice. 
Inconsistent 
protocols used due 
to types of patients, 
insurance, family 
support, etc. 




systems to support 
information 
exchange relative to 




level and physician 
along with 
educating patients 
Not educated on 
PCOS.  “Not 






Leadership To what extent do 
the leaders within 
the practice 
environment support 
(both visibly and 
behind the scenes) 
the implementation 
of the CPG? 
The support of the 
staff and other 
providers in the 
office. 









Staff Nurses and 
Nurse Educators) 
Does the staff have 
the necessary 
knowledge and 
skills?  Which 
potential target 
group is open to 
change and new 
ideas?   To what 










PCOS and  ability 
to utilize the 
guidelines 
appropriately 
Lack of interest or 









systems exist to 





being a part of  
office infrastructure 
 
Lack of resources on 
PCOS and Obesity 




Are the necessary 
human, physical and 
financial resources 




with involvement of 
the diagnosis and 
treatment of PCOS 
Unclear of updated 
guidelines for 
obesity and PCOS 
Interdisciplinary 
relationships 
Are there positive 
relationships and 
trust between the 
disciplines that will 
be involved or 
affected by the 
CPG? 
Support and use of 
these guidelines will 
allow for other 
disciplines to be 
educated on this 
disease 
Misunderstanding of 
the disease process 
across different 
specialties causes 
mixed focus of the 
diagnosis and 
treatment of PCOS 
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Patients Are patients happy 
with results of new 
guidelines 
Results of patient 
evaluations 
Lack of desire for 
the patients to fill 
out evaluations 
 
 According to the Endocrine Society, treatment of obesity in the PCOS patient is 
not associated with improvement in symptoms (Endocrine Society, 2013). The purpose of 
this literature review is to present research to substantiate the importance of weight loss 
in PCOS in the reduction of symptoms.  It then continues to discuss improvement in co-
morbidities with the introduction of liraglutide as a treatment.  Weight loss as well as the 
use of liraglutide decrease inflammatory markers, especially TNF-a, which are key in the 
pathophysiology of PCOS (Gonzalez, 2015; Gagnon et. al, 2015). 
Tumor Necrosis Factor-alpha 
Tumor Necrosis Factor-alpha (TNF-α) is a pro-inflammation cytokine which 
encourages a wide range of reproduction related disorders (Gagnon et. al., 2015).  
Genetic and epigenetic expressions of this inflammatory marker lead to excess 
production of TNF-α.  Because of excessive TNF-α, elevated production of other 
androgens in the system produce the classical symptoms of PCOS (Fauser et. Al, 2012). 
These androgens include testosterone, DHEA-S, insulin among others. 
While obesity is well known to create a pro-inflammatory state, with increased 
levels of TNF-α, recent literature suggests PCOS patients exhibit increased levels of these 
inflammatory markers independent of obesity (Gonzalez, 2015).  Inflammatory markers 
also secrete abnormally in response to dietary components, such as glucose. This 
promotes a greater pro-inflammatory and oxidative state, which is elevated when obesity 
is present (Gonzalez, Sia, Shepard, Rote & Minium,2014).  
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Genetic and Epigenetic Polymorphisms of TNF-α in PCOS patients have been 
confirmed versus control groups in recent studies (Gan & Nalliah, 2015).  Hector et. Al 
(2001) demonstrates high serum levels of TNF-α in PCOS patients. TNF-a biomarkers 
have been identified as a screening for potential candidates and their risk for developing 
PCOS (2015).  The following diagram is a simplified algorithm to how TNF-a causes 
insulin resistance. 
Elevated levels of TNF-α contribute to insulin resistance through post receptor 
restraint of insulin receptors.  TNF-α impedes insulin uptake leading to a decrease in 
insulin sensitivity.  Consequently, hyperinsulinemia occurs as a compensatory 
mechanism, which in return, promotes an elevated androgen state and increase in 
adiposity (Gonzalez, F., 2015). 
Since the discovery of TNF-α, the understanding of the various effects on the human 
body is increasing.  The pathophysiology of diseases linked with this marker 
 




involves multiple organ systems.  TNF-α receptors can be located on virtually every cell 
of the body.  With this increase in understanding the role of TNF-α in diseases an 
increase in therapeutic agents rise (LaDuca & Gaspari, 2001) 
In 1999 Dr. Gonzalez states that circulating TNF-a is elevated independent of 
obesity in PCOS (Gonzalez et. al., 1999).  Dr. Gonzalez discusses multiple connections to 
PCOS and TNF-a in his peer reviewed article, Inflammation on Polycystic Ovary 
Syndrome: Underpinning of insulin resistance and ovarian dysfunction (2012).  Along 
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with this, research continues to have no definite etiology of PCOS.  Recent literature 
points toward a pattern consistent with inflammatory markers’ response to genetic 
mutations and epigenetic factors which could support an etiology to this syndrome 
(2012). 
 PCOS subjects have been shown to produce elevated levels of TNF-α in response 
to glucose independent of obesity. Glucose intake along with acute hyperglycemia causes 
insulin resistance. Insulin resistance becomes a potent activator of several inflammatory 
cellular pathways (Khodabandehloo et al., 2015).  Of significant importance, 
physiological changes occur in the presence of excess insulin, resulting in a greater 
luteinizing hormone (LH) response. This increase in LH function contributes to the 
abnormal ovulation and increase in androgens observed in PCOS patients (Franks, 2011).  
Further research involving the pathophysiology of PCOS is the elevation of TNF-
α from the ovaries that elevate insulin and androgen levels (Hector et. Al, 2001).  Recent 
genetic research is on the brink of identifying TNF-α mutations in the genetic sequences 
that are unique to PCOS patients (Gan & Nalliah, 2015).  Gan and Nalliah (2015) have 
verified this TNF-α mutation could potentially be related to lowering GLP-1 production 
and uptake in the cells initiating the PCOS disease process. 
GLP-1 Agonists 
The purpose of this project is focused research regarding the parallel between 
obesity and the obese PCOS patient in the therapeutic benefit of liraglutide, a GLP-1 
agonist.  An important parallel in treating with liraglutide is a decrease in inflammatory 
markers, like TNF-α, and weight.  Elevated TNF-α levels lower GLP-1 production in the 
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gut as well as GLP-1 uptake in the peripheral organs (Gagnon, 2015).  An observational 
research study concludes that GLP-1 inhibition occurs in PCOS patients independent of 
BMI or oral contraceptive use during a three hour glucose tolerance test.  TNF-α was not 
tested in this research (Aydin, Arusoglu, Koksalt, Cinar, Aksoy & Yildiz, 2014 ) 
Molecular cardiologists published a study in 2013 correlating GLP-1 agonists 
with a decrease in the over-expression of TNF-α in mice who were fed a high fat diet for 
up to 32 weeks versus the mice control group (Noyan-Ashraf et. al., 2013).  Their 
conclusion supports GLP-1 in the activation of several cardio-protective pathways in 
vitro (2013).  
The research for GLP-1 agonist treatment of weight loss in PCOS, independent of 
BMI is limited and the subject numbers are small.  In the literature review, GLP-1 
agonists have been extensively researched for T2DM, obesity and non- alcoholic 
steatohepatitis (NASH).  Other research supports GLP-1 agonists with treatment for 
hypertension, metabolic therapy, Alzheimer’s disease and antipsychotic medication 
induced obesity (Hoang et. al., 2015; Ishoy, Fliip, Vilsboll, Glenthoj, & Bjorn, 2013).  
The following diagram in Figure two demonstrates GLP-1 and insulin on the cell 
receptors. 
Multiple peer-reviewed research outcomes identify similar results involving GLP-1 
induced weight loss in patients who have diagnoses other than PCOS. In 2013, a 
randomized controlled trial compares antidiabetic medications, including GLP-1 agonists 
for treatment of T2DM (Brady, Davies, Gray, Saeed, Smith, Hanif & Khunti, 2013).  




Although weight loss is a secondary outcome liraglutide, which is a GLP-1 agonist, did 
statistically find weight loss in this group (>-1kg).  This was the first randomized 
controlled trial comparing a sulfonurea to a GLP-1 receptor agonist in patients with 
diagnosed T2DM who were fasting during Ramadan.  It is a 12 week study with 70 
subjects finishing the trial (2013). 
The second review is a study involving long-term efficacy and safety in 
comparing liraglutide, glimepiride and placebo with T2DM.  It is randomized to 
liraglutide, placebo, or glimepiride with all to include metformin.  It is a two year 
retrospective study from patients who enroll in the LEAD-2 study and continues after the 
26 week trial was complete.  Weight loss with liraglutide is significantly greater than 
with metformin therapy (p=0.0378) (Nauck, Hermansen, Thomsen, During, Shah, 
Tankova, Miltha & Matthews, 2013). 
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The third review involves a 12-week prospective randomized open-label study 
involving metformin or liraglutide with a primary endpoint of weight loss.  The PCOS 
subjects are diagnosed by Rotterdam criteria.  A statistical weight loss is observed (Sever 
et. al., 2015).   
The fourth review involves an observational study from Denmark.  The aim is to 
evaluate liraglutide on weight loss with obese and overweight women with PCOS.  
Treatment is significant in the overweight and obese women on liraglutide.  A mean 
decrease of the BMI of 3.2 kg/m2 is found (Rasmussen & Lindenberg, 2014). 
The fifth review involves liraglutide and improvement of hypertension and 
metabolic perturbation in a rat model of PCOS.  A secondary outcome involves noted 
weight loss.  A significant decrease in body weight (p<0.01) is measured.  Utilizing 
research in a very controlled setting allows for more accurate results in the endpoints 
being studied (Hoang et. al., 2015).   
The sixth review is conducted as a randomized control trial to research the question 
involving GLP-1 receptor agonist and maintenance of weight loss due to a decrease in 
plasma leptin.  This is an interesting description of leptin in the methodology and results. 
The subjects are randomized, after a 12 percent weight loss into the treatment with GLP-
1 agonist and the control being without treatment.  The study is able to conclude that 
GLP-1 agonists maintain the 12 percent weight loss for one year and could prevent 
prediabetes and obesity (Iepsen, Lundgren, Dirksen, Jensen, Pedersen, Hansen, Madsbab, 
Holst & Torekov, 2014).  
Assimilating the Research 
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This researcher begins to review case studies of patients and gather evidence based 
research to cultivate a trend of family history, genetics, epigenetics, medical histories, 
lifestyle failures and past medical therapies corresponding with the diagnosis of obesity 
and co-morbidity of PCOS.   A common theme in the research involves gut hormones 
and the effect of insulin resistance in these women.  This research leads to the connection 
of insulin resistance (IR) to GLP-1 (Drucker, 2006).  
 Next, this research attempts to integrate the similarities of inflammatory markers 
and insulin resistance in PCOS and obesity. This integration leads to a consistent theme.  
These patients with increasing inflammatory markers complicate the ability to improve 
without intervention. Once the weight gain begins, increased adipose tissue complicates 
the overall hormone dysregulation with the inflammatory markers produced from the 
tissue.  It is like a train leaving the station.  Because of this hormone dysregulation, if 
affected women exercise and eat minimally, the insulin resistance will not allow for 
metabolism of adipose.  Lifestyle changes have shown little result (Endocrine Society, 
2013).  
  This is where GLP-1 comes into play. GLP-1 is an incretin hormone secreted in a 
nutrient dependent dose.  It stimulates glucose dependent insulin secretion (Drucker, 
2006).  GLP-1 receptors are not only located in the pancreas, but also the kidney, lung, 
heart, and the peripheral and central nervous system (2006). These are all the areas 
affected by obesity and PCOS as mentioned earlier in the literature review.  
 Both lean and obese women with PCOS show mutated alterations in the secretion 
of GLP-1 both fasting and post-prandial (Aydin, Arusoglu, Koksai, Cinar, Aksoy, & 
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Yidliz, 2014). Recently researchers have found a strong link with PCOS to IR, a genetic 
condition often associated with diabetes (Hoffman et. al., 2016). IR is a condition in 
which muscle, fat, and liver cells do not respond properly to insulin and thus cannot 
easily absorb glucose from the bloodstream.  This causes production of increasingly 
higher levels of insulin to assist with entry of glucose into the cell.  This exacerbates the 
disease process causing more insulin resistance, potential weight gain, and worsening of 
hormone dysregulation (Gonzalez, 2015; Gonzalez, Sia, Shepard, Rote, & Minium, 
2014). 
Chapter Summary 
The purpose of this literature review is to educate the reader on updated research 
and paradigm shifts in the diagnosis and treatment of the obese PCOS patient.  The 
disease process is a culmination of both genetic and epigenetic expressions of each 
affected female.  Treatment options have been limited as the true etiologies have not been 
identified at this juncture.  This research delineates the links between obesity and PCOS 
in order to educate nurse practitioners on a new treatment option for PCOS. 
Identification and understanding of the individualized hormone dysregulation in 
PCOS is vital.  One size does not fit all with this disease process.  Once the diagnosis is 
made, distinct treatment plans for each patient is imperative based on a very thorough 
history and physical. Laboratory studies and other diagnostics should be addressed. The 
necessity to align hormone regulation by lowering inflammation and restoring insulin 
sensitivity is the hallmark of PCOS (Gonzalez, 2015).  
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Once the initial inflammation has been addressed research is demonstrating that 
obesity, infertility, glucose dysregulation, and hormone dysregulation improves.  The 
patient’s overall self- esteem, quality of life and overall health improve. PCOS is a very 
complex disease process with divergent assumptions of causes and treatments.  The 
origins of PCOS must be recognized. Chapter III discusses the research methodology, 


















This chapter includes the research design, samples, instrument utilization, and the 
analysis of the statistical outcomes.  This study is designed to evaluate primary care 
providers, specifically, nurse practitioners and family nurse practitioner students, in their 
knowledge of the obese patient with PCOS before and after a Continuing Education (CE) 
presentation on PCOS.  The review of the literature discloses the updated research and 
paradigm shifts in the diagnosis and treatment of the obese PCOS patient.   
Research Design, Conceptualization and Measurement 
The study utilizes a quasi-experimental design for measuring knowledge of the 
participating learner and their understanding of PCOS based on recent guidelines for 
diagnosis, assessment, and treatment of this disorder.  Two practice guidelines are 
bridged in order to apply up-to-date treatment in the obese, PCOS patient. 
Implementation of the quantitative study allows for the review of how participating 
learners are improving their education of obesity in PCOS after participating in the 
presentation (Hoy & Adams, 2016). Using this style of statistical analysis allows for an 
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objective approach and decreases the chance of the researcher becoming overly involved.  
It also decreases potential complications early in the study (2016). 
The decision to utilize a quasi-experimental design allows for testing and analysis 
evaluation to identify the strength and dissemination of the education presented during 
the CE.  There is no control group.  This study utilizes a randomized sample due to the 
potential small size of the participant group.  The questionnaire includes a demographic 
section in order to identify the representation of the sample. 
Figure 3.  Project Algorithm 
 
 
The Continuing Education program, which is presented as face-to-face presentation 
with the use of PowerPoint slides, introduces an updated approach in PCOS diagnosis 
and treatment in the overweight/obese population.  It is anticipated that the goals of this 
project will be met.  It is anticipated that 100 percent of the learners will be able to 
Testing complete, 










process and synthesize the information in order to contemplate practice changes at their 
place of employment.  
Research Questions 
The following questions are the focus of the results from the evaluation of the pre-
post-test and diagnosing and treating PCOS: 
1. Will the Continuing Education presentation on the new PCOS Guideline increase 
the knowledge base of the correlations between obesity and PCOS? 
2. Will the Continuing Education presentation on the new PCOS Guideline increase 
the knowledge base of diagnosing the patient with PCOS and obesity? 
3. Will the Continuing Education presentation on the new PCOS Guideline increase 
the knowledge base of inflammatory co-morbidities and PCOS? 
4. Will the Continuing Education presentation on the new PCOS Guideline increase 
the provider’s knowledge of prescribing weight loss medications for the obese 
patient with PCOS? 
Settings and Participants 
The participants’ involvement in this research project includes attendance at the 
Continuing Education presentation on the new PCOS Guideline by licensed practicing 
nurse practitioners, as well as Family Nurse Practitioner (FNP) students enrolled in a 
Master of Science in Nursing FNP program.  These attendees are members of the 
“4 State APN Group” which is a group of Nurse Practitioners in the Kansas, Missouri, 
Oklahoma and Arkansas areas who meet to discuss the latest issues on a monthly basis.  
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Additionally, nurse practitioner students from the same areas are invited to join this group 
each month. 
 In order to complete and receive CE’s for the presentation, the pretest and 
posttest are mandatory.  The level of knowledge each participant possesses previous to 
the presentation is important in order to validate the increase in knowledge base after 
listening to the PCOS Guideline presentation.  The participants are able to disseminate 
the information and utilize it in their daily practice in order to have the confidence to 
appropriately diagnose and treat the female obese patient with PCOS. 
Inclusion/Exclusion Criteria 
 Inclusion criteria for this study involved all licensed practicing nurse 
practitioners, as well as Family Nurse Practitioner (FNP) students enrolled in a Master of 
Science in Nursing FNP program who attended the 4 State APN Group monthly meeting. 
The monthly meeting of the 4 State APRN Group was held at The Sullivan Clinic.  The 
attendees completed the pretest, listened to the lecture with PowerPoint presentation and 
then completed the posttest.  The participants were required to be a licensed nurse 
practitioner or a nurse practitioner student.  No other exclusion criteria were recognized. 
Protection of Human Subjects 
 This research capstone project falls under the status of exempt.  The population of 
participants included adult nurse practitioners or nurse practitioner students over the age 
of 18.  This study required a specific population which did not include children under 18, 
prisoners, specific ethnicity groups, or specific racial populations. There is no harassment 
or deception completed in order to obtain subjects for the continuing education offering.  
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In order to maintain confidentiality of the test results, each participant was given a 
specific code for the results.  The participants are not placed at risk for a criminal or civil 
liable issue in completing the webinar and test questions.  The participants are not placed 
at risk of damage to their reputation, finances, employment status or emotional health. 
 This research utilizes the criteria for the Committee for the Protection of Human 
Research Subjects (CPHRS) at Pittsburg State University, Pittsburg, Kansas.  The 
information being obtained from the testing was utilized only for this research project.  
Completed test results are stored on a HIPPA compliant computer belonging to this 
researcher.  Hard copies of the results will be stored in a locked filing cabinet in a locked 
room in the Irene Ransom Bradley School of Nursing.  All data will be kept for a 
minimum of two years in a protected file then deleted from the hard drive. 
Ethical and Administrative Considerations 
 Prior to seeking the consent of nurses agreeing to this research, authorization was 
be verified by an officer of the 4 State APN Group.  Written informed consents were 
included prior to the first question of the demographic portion of the test.  All data were 
considered confidential.  Prior to the beginning of the presentation, all pretests and 
posttests were numbered to assure anonymity.  Participants were verbally instructed they 
have a right to withdraw from the research at any time.  
The ethical considerations potentially placing the participants in jeopardy for this 
capstone project were minimal.  The design of the study was a quasi-experimental 
quantitative study involving the use of a pretest/posttest method. As previously stated, the 
demographics and results of the testing were handled in a confidential manner.  The 
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anonymity code system was stored in a different secure file on this researcher’s 
computer. A roster requiring name, state of licensure and Advanced Practice Registered 
Nurse (APRN) license number was utilized to confirm the validity of the participant as a 
licensed nurse practitioner and to document the status of the participant as a student. 
Instrument 
 This quasi-experimental project utilized a lecture and PowerPoint presentation 
which is followed by a pretest and posttest.  The instrument included an index of close-
ended questions for each dimension with the pretest having additional demographic and 
professional practice questions not repeated on the posttest, (Appendix A). The original 
instrument utilized up-to-date evidence based literature from current guidelines and a 
comprehensive literature review (see Appendix A: Provider PCOS and Obesity Survey; 
pretest and posttest).  The test questions were based on the literature review incorporating 
current practice guidelines along with research to support the inflammatory connection of 
PCOS and obesity.  The pretest index was comprised of four main dimensions not 
including pretest professional demographic questions.  These four categories were chosen 
to narrow the immense research on PCOS to be more focused on the connection of 
PCOS, obesity, inflammation, co-morbidities, diagnosis and treatment for weight loss in 
these patients.   
These four dimensions included: (a) Inflammatory connections between obesity 
and PCOS; (b) diagnosis (c) inflammatory co-morbidities; and (d) medication 
management in the obese, PCOS patient.  The posttest index followed the same format 
excluding the professional demographic questions.  The style of questions included 
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multiple choice, True or False, and case studies.  These questions addressed the following 
research questions.  There were four questions per category.  Each category included four 
related questions.  Each correct answer will be given a one.  An incorrect answer will be 
given a zero.  Each category has a possibility of a zero to four in sum total. 
Dimensions 
 
A. Will the Continuing Education presentation on the new guideline for PCOS 
increase the knowledge of the inflammatory correlations of obesity and PCOS? 
PCOS Index with Four Dimensions 
 




b. Polycystic Ovarian Syndrome 
c. Insulin Resistance 
d. GLP-Production 
 
2.  Only patients who have both Polycystic Ovarian Syndrome and obesity have      
abnormalities in Tumor Necrosis Factor Alpha? 
 
a.   True 
b.   False 
 
3. Glucose intake alters Tumor Necrosis Factor Alpha in Polycystic Ovarian                         
Syndrome and causes: 
a.   A decrease in insulin 
b.   An elevation in androgens 
c.   A decrease in Luteinizing Hormone (LH) 
d.   None of the above 
 
4. An elevation in Tumor Necrosis Factor Alpha decreases the production and  
increases the resistance of GLP-1 in PCOS.  This correlation also occurs in obesity.  This 
results in: 
a.   Insulin Resistance 
b.   Weight Gain 
c.   Glucose Elevation 




B.  Will the Continuing Education presentation on the new guideline for PCOS increase 
the provider’s knowledge base with diagnosing the patient with PCOS and obesity? 
 
        5. Current recommendations at the national American Diabetes Conference in 2016  
 involving a name change of PCOS would be? 
 
a. Complex Metabolic Syndrome 
b. Metabolic Reproductive Syndrome 
c. Reproductive Metabolic Syndrome 
d. Androgen Reproductive Syndrome 
e. None of the above 
 
      6.According to current practice guidelines for PCOS from the Endocrine Society,  
         which guidelines are recommended in diagnosing PCOS? 
 
a.  Rotterdam criteria  
b.  NIH criteria 
c. AE-PCOS Society criteria 
d.  None of the above 
 
7. According to current practice guidelines for PCOS what screening             
measurements are assessed to screen for adiposity in PCOS? 
 
a.   BMI 
b.   Body Fat Composition 
c.   Waist Circumference 
d.   A and C 
 
8. According to current practice guidelines what lab testing should be routinely 
ordered to diagnose patients with PCOS? 
 
a.   TSH 
b.   Hemoglobin A1C 
c.   Lipid panel 
d.  Insulin level 
C.  Will the Continuing Education presentation on the new PCOS guidelines increase the 
knowledge base of inflammatory co-morbidities and PCOS? 
 




a.   Nonalcoholic fatty liver disease 
b.   Diabetes 
c.   Sleep apnea 
d.  Pancreatitis 
   10.   According to the National Institute of Health, PCOS patients, with obesity 
have co-morbidities that worsen their disease state.  These include: 
 
a. Vitamin D deficiency 
b. Prediabetes 
c. Hypertension                      
d. All the Above 
  
  11.  Mental health conditions are a co-morbidity of PCOS? 
 
a.   True 
b.  False 
 
  12.   The following is a case study regarding co-morbidities in PCOS. 
 
“Jane Doe,” age 52 was recently released from the hospital with stage four uterine 
cancer after recently having both legs amputated from Insulin Dependent Diabetes 
Mellitus which is uncontrolled.  She decided to not undergo any intervention for 
her cancer except for her Total Abdominal Hysterectomy.  She tells the doctors 
and her family that she is just tired. 
 
  ...”I’m sorry family, friends, and health care providers.  I have attempted to find 
someone since I was in high school to noticing my:  missed periods, severe pelvic 
pain, weight gain, excessive hair, acne, insomnia, joint pain, edema, fatigue, 
episodes of rage, and low self-esteem.  I ended up on lots of antidepressants and 
occasional in-patient psychiatric hospitalizations.  But you know, they all said it 
was in my head.  I was so confused because I literally ate like a bird but 
continued to gain weight.  No one believed me.  My parents took me to many 
specialists and they did say that I had Polycystic ovarian syndrome and 
prescribed birth control pills.  I couldn’t take them.  Then I had someone 
prescribe 2000 mg of Metformin a day, ’tore my stomach up.  Didn’t want 
anything to do with that crap. 
 Years went by. Someone felt sorry for me and married me.  We tried for 
years to have a baby; infertility drugs and all.  We did in-vitro fertilization and 
after $50,000.00 and three attempts I did have a baby girl.  She saved my life 
mentally.  My focus was on her although I knew something was very wrong with 
me.  This time in my life was hell.  I was crazy most of the time, at least I thought.  
I kept gaining weight, feeling even more reclusive.  I developed diabetes, 
hypertension, and fatty liver disease.  I was prescribed so much medicine.  And 
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since I hated metformin, my health care provider started me on insulin.  That’s 
when my life changed forever. 
 I kept gaining weight.  I ended up with heart disease and multiple 
diagnoses with more medicine.  Over 300 pounds at that point, I had a heart 
attack.  Quadruple Bi-pass.  Next, a divorce.  My husband was done and told me 
that my health care providers said if I would just eat right and exercise that I 
would have been o.k.  I was on diets and even had a gastric band.  I felt so 
defeated.   
 My daughter was having the same problems and turned 18.  She went to 
her local health care provider who sent her to someone who specializes in PCOS.  
She was 200 pounds, no periods, and excessive hair and acne.  This provider 
started her on weight loss medicine, spironolactone for hyperandrogenism, 
liraglutide, and a low-glycemic food plan.  In one year she lost 50 pounds, 
regained normal cycles, was sleeping, and developed a positive self- image. 
 Recently that health care provider sat down with me and cried with me 
after my decision to not undergo any treatment for my cancer.  She told me if I 
would have been diagnosed and treated appropriately that I would probably have 
been a healthy and vibrant woman at this time.  I just hope the new information 
on PCOS gets out so that women like me can be saved from this life imprisoned 
due to a misunderstood syndrome.” 
 
      12. When reading this case study consistent symptoms and health problems being a  
co-morbidity of PCOS, what appears to be the underlying issues causing this 
patient to fail? 
 
a.   Self-Motivation 
b.   Depression 
c.   Inflammation 
d.   Health Care Providers 
 
D.  Will the Continuing Education presentation on the new PCOS Guideline increase the 
provider’s knowledge of prescribing weight loss medications for the obese patient with 
PCOS? 
 
    13. According to current practice guidelines in PCOS___________ is recommended  
for weight loss in the PCOS patient who is overweight or obese? 
 
a.   Metformin 
b.   Calorie restricted diet 
c.   Phentermine 
d.  Orlistat 
    14.   Which is not recommended in the treatment of obesity in PCOS according to the  




a.   Liraglutide 
b.   Exercise 
c.   Diet Control 
d.  Reduced calories 
The following are case studies. Please read the following case study and respond to the 
questions based on the case.  
 
15. "PR" is a 41-year-old female who comes to the clinic for a new patient 
consultation. At today's visit, she is 5 feet 3 inches tall and 140 pounds. Her body 
mass index is 25. She is not worried about her weight.  She is more concerned 
with no menses and hair growth on her abdomen and back.  She has severe acne 
that bothers her self-esteem.  Only one pregnancy was induced by Clomid and 
weight loss. According to the 2016 AACE/ACE clinical practice guidelines for 





c. Bariatric Surgery 
d. Phentermine 
 
You obtain “PR” family history. Her mother and grandmother are both obese and have 
been diagnosed with type 2 diabetes and hypertension. Both had a difficult time getting 
pregnant.  They had severe issues with their cycles and losing weight.  There was no 
family history of thyroid cancer or pancreatitis.  Her previous history was free of those 
diagnoses as well. Her lab work showed elevated fasting insulin at 23, low B12 at 145, 
low Vitamin D at 17, Hgb A1c of 5.9 percent. 
 
     16. “PR” did not tolerate the Liraglutide, metformin, or orlistat.  After six months  
she gained 30 pounds.  What is the next intervention after lifestyle and diet 




c. Roux-En-Y procedure 
d. Gastric Bi-Pass 
 
Content Validity 
 Evaluating the validity of this index came from the literature review.  The studies 
included areas of obesity and PCOS recently published which illustrated validity of each 
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test question in the instrument.  This Index was developed to test the knowledge of best 
practice guidelines in PCOS and obesity.  Three nurse practitioners working in the area of 
women’s health or family practice were planned to evaluate the instrument based on their 
expertise.  This was not completed due to the time frame available for presenting the 
study.  An evaluation survey was offered to the initial presentation participants to test the 
validity of the instrument. 
Procedure 
The project consisted of a continuing education presentation utilizing a PowerPoint 
to describe current evidence based practice guidelines and a comprehensive literature 
review that related to PCOS in the obese patient.  The participants were members of the 4 
State APRN Group.  Incentives were offered to gain voluntary participation in this 
project which included a pending one hour Continuing Education credit from the 
American Academy of Nurse Practitioners and a catered Italian dinner. 
The continuing education presentation was delivered as the keynote presentation for 
the monthly 4 State APN Group. The continuing education program was presented in 
collaboration with American Academy of Nurse Practitioners, pending approval of the 
research for one hour of Continuing Education. The Sullivan Clinic provided a meal for 
the participants. The participants were given the pretest as they arrived for the meeting.  
The presentation was viewed during the dinner.  After the dinner and the presentation 
was complete, the posttest was given followed by a question and answer session.   
With completion of the education and posttest, an 11 question survey was given to 
validate the presentation and designed instrument for this study with two being open-
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ended questions.  The questionnaire was based on a four point Likert scale with 4 = 
strongly agree, 3 = agree, 2 = somewhat disagree, and 1 = strongly disagree.  The 
questions included whether the participation in the activity allowed for better 
understanding of the four dimensions of the designed instrument.  The second question 
evaluated how knowledge was presented.  The third question evaluated the 
appropriateness of the presentation utilizing the design instrument.  The fourth question 
evaluated the cohesiveness of the content topics with the designed instrument.  The fifth 
question evaluated the fair and balanced coverage of the instrument.  The sixth question 
evaluated the disclosure of any conflict of interest.  The seventh question evaluated if the 
instrument was free from commercial bias.  The eighth question evaluated the 
recommendation to colleagues.  The ninth question evaluated the enhancement of current 
knowledge base with the use of the instrument. 
After the confidential evaluation was completed by the 18 participants, the forms 
were placed in an envelope and secured in a safe at the Sullivan clinic. At a separate time, 
the 18 evaluations were tallied having 9 Likert scale questions.  Scores were tallied.  
After totals of each questions were figured, Cronbach’s Alpha was utilized to evaluate 
internal validity. 
Data Collection and Measurement 
This research consisted as a sample of convenience based on the quasi-experimental 
design for an index correlating four dimensions from the literature review.  (Babbie, 
2014). The population for this capstone project included nurse practitioners and nurse 
practitioner students from Kansas, Missouri, Oklahoma and Arkansas who attended the $ 
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State APN Group’s monthly meeting in October, 2016.  The meeting was held at The 
Sullivan Clinic in Frontenac, KS.  The 4-State APN is an area group of professionals that 
meet monthly.  It was voluntary and no monetary compensation was offered to complete 
the webinar. 
The pretest was secured in a confidential manner during the presentation. All data 
were kept confidential and all participants were kept anonymous. To measure the 
dependent variable, the correct response was valued as a one. The incorrect response was 
valued as zero. The total scores were tallied.  The totals were divided by the number of 
correct answers to give a mean value.  The highest total value was 16 with the lowest 
value being zero. There were four dimensions which had four questions each.  Each 
dimension was tallied from a zero to four to evaluate the number of questions correct.  
These values were converted and presented as a percentage.  Separating the total correct 
answers divided into four dimensions allowed for feedback analysis in the validity of the 
presentation and instrument. 
Statistical analysis was performed utilizing Excel in spreadsheet format.  
Statistical significance allowed for a probability level acceptable as p<0.05. A paired t-
test was conducted on the pretest and posttest results; one = yes, zero = no.  Evaluation 
measures assessed within the parameters of each dimension of the overall project.  
Quantitative analysis used descriptive statistics and standard deviation to identify whether 
pre-test evaluations were statistically significant in comparison with post-test data.  The 




Evaluation Measures Linked to Objectives 
 Evaluation measures were linked to the objectives utilizing the logic model 
(Figure 2).  This project measured the participants’ knowledge of the diagnosis and 
treatment of obese PCOS patients with updated treatment guidelines before and after an 
educational program. The measured outcomes being evaluated were diagnostic criteria, 
diagnosis, pathophysiology, and treatment. A positive outcome was indicated by an 
increase in percentage of correct answers posttest.  The long term goal of this research 
was to increase the awareness and knowledge of the diagnosis and treatment of the PCOS 
patient with obesity.  Due to time this was not able to be measured with this research. 
 The research instrument was in a pretest and posttest format.  The dependent 
variable consisted of 16 questions.  A survey tool was established specific for this 
research since it involved a paradigm shift in the diagnosis and treatment of PCOS in 
obesity.  It included multiple styles of questions including true and false, multiple choice, 
and case studies. An over-all score was utilized for the results. Table 7 describes the 
projected results of this research project. 
Table 7.  Objectives, Measurements and Outcomes 
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With PCOS occurring in over 5 million women of childbearing age, continuous 
therapies and understanding of the cause is imperative.  This researcher has witnessed 
hundreds of case studies personally with both positive and negative outcomes because of 
the lack of FDA approved therapies for treatment as well as a misunderstanding of the 
disease process alone.    
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GLP-1 agonists have been shown in small studies across the world to decrease 
weight and inflammation in these affected women.  Hopefully through persistence and 
education, this research is part of the revolution of treatments and further research for this 
continued complex disease which has imprisoned the quality of life of millions of women 
thus far. 
This project consisted of an educational program, the design of a pretest and 
posttest instrument in the form of an index, and validation of the instrument in the form 



















 The findings in this scholarly project were analyzed to determine if an increase in 
knowledge emerged.  The potential increase in the knowledge acquired regarding PCOS 
practice guidelines following a continuing education presentation on new guidelines for 
obese, PCOS patients.  A group of nurse practitioners and nurse practitioner students 
listened to the presentation and observed a PowerPoint presentation after a pretest over 
the contents of the presentation.  A posttest was completed after the presentation was 
given.  The sample included 18 total participants at this evening event. The data were 
analyzed providing quantitative data.  The survey provided information on the 
educational offering and the posttest validated whether an increase in knowledge level of 
PCOS practice guidelines was observed.  Following the collection of demographic data, 
the pretest data were collected regarding current guideline information and the 
pathophysiology of inflammation and PCOS.  After the presentation, the same test was 
given to the subjects.  The pretest and posttest contained sixteen questions separated into 
four distinct domains: 
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1. Will the Continuing Education presentation on the new PCOS Guideline 
increase the knowledge base of the correlations between obesity and PCOS? 
2. Will the Continuing Education presentation on the new PCOS Guideline 
increase the knowledge base of diagnosing the patient with PCOS and 
obesity? 
3. Will the Continuing Education presentation on the new PCOS Guideline 
increase the knowledge base of inflammatory co-morbidities and PCOS? 
4. Will the Continuing Education presentation on the new PCOS Guideline 
increase the provider’s knowledge of prescribing weight loss medications for 
the obese patient with PCOS? 
Demographic Data 
 The demographic data gathered from the participants included practice setting and 
years of experience and is Presented in Table 5.  Thirty-three percent (N=6) of 
practitioners were employed in a Family Practice setting.  Nurse practitioners employed 
in Women’s Health included one participant (N=1 or six percent).  Six percent (n=1) 
were employed in the Emergency Department. The student participants consisted of 17 
percent (n=3) of the subjects.  Nurse Educators represented 22 percent (n=3). There was 
one Cardiothoracic Nurse Practitioner in the group of subjects which represented six 
percent of the population.  Wound Care nurse practitioners represented eleven percent of 
the population (n=2). 
 The total years as a nurse practitioner was calculated from 0-3 years, 3-5 years, 5-
10 years, and 10-20 years.  Thirty-three percent represented 0-3 years of clinical 
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experience as a nurse practitioner.  Six percent represented 3-5 years.  Thirty-three 
percent represented 5-10 years and twenty-eight percent represented 10-20 years.   
 In a yes or no question, each participant was asked if they were currently taking 
care of patients with PCOS.  The responses revealed that 28 percent of the subjects were 
currently taking care of patients with PCOS. 
Table 8. Demographic Information of Attendance at Presentation 
 
Pretest and Posttest 
 All of the subjects participating in the project were given a pretest prior to the 
presentation and a posttest followed.  The testing was grouped according the name on the 






















the 16 questions.  These questions were divided into four domains to make up an index.  
The first domain included questions on the inflammatory correlations of obesity and 
PCOS.  The second domain included questions on the diagnosis of a patient with obesity 
and PCOS.  The third domain included questions on the inflammatory co-morbidities and 
PCOS.  The fourth domain included questions regarding the new guidelines in 
prescribing weight loss medication to the obese female with a co-morbidity of PCOS. 
Results  
Quantitative data. Each Dimension was tallied separately with 4 possible correct 
answers within each of the four categories.  The mean pretest score for Dimension one 
was 3.0556 with a standard deviation of 0.9376 in the pretest group.  The mean posttest 
score for Dimension one was 3.4444 with a standard deviation of 0.70479.  The 
differences in the pretest score and the posttest score had a mean of -0.3889 
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Table 9.  Dimension One Pretest/Posttest Scores
 
with a standard deviation of 1.33456. The difference in test scores was not found to be 
statistically significant although most respondents had an increase in posttest scores as 
evidenced in Table 9.  
The mean pretest score for Dimension two was 2.2222 with a standard deviation of 
0.54832 in the pretest group.  The mean posttest score for Dimension one was 3.1667 
with a standard deviation of 0.87549.  The differences in the pretest score and the posttest 
score had a median of -0.9444 with a standard deviation of 0.93769.  Statistical 
significance was found at p<0.001.  The majority of respondents had an increase in  
posttest scores as evidenced in Table 10.  
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Table 10. Dimension Two pretest and posttest results
 
The mean pretest score for Dimension three was 2.2222 with a standard deviation 
of 0.8782 in the pretest group.  The mean posttest score for Dimension one was 2.3333 
with a standard deviation of 0.76696.  The differences in the pretest score and the posttest 
score had a mean of -0.1111 with a standard deviation of 1.02262. Statistical significance 
was not found with a p> 0.05. Some respondents had a decrease in posttest scores as 






Table 11.  Dimension Three Pretest/Posttest Scores 
 
The mean pretest score for Dimension four was 0.7778 with a standard deviation 
of 0.80845 in the pretest group.  The mean posttest score for Dimension one was 3.3333 
with a standard deviation of 0.84017.  The differences in the pretest score and the posttest 
score had a mean of -2.5556 with a standard deviation of 1.09664.  All respondents had 
an increase in posttest scores as evidenced in table 12.  Statistical Significance was found 






Table 12.  Dimension four Pretest/Posttest Scores 
 
Validity of the index. Due to time constraints of the acceptance date of the 
proposal and the change of dates in the project presentation, validity of the index was 
tested at this presentation with all 18 subjects completing the 4 point Likert scale 
questionnaire with a place for open ended suggested changes.  Nine questions were 
asked.  There were no open ended suggestions noted.  Cronbachs’ Alpha was utilized to 










Table 13.  Paired t-test sampling revealing paired differences 
 
 
pretest, posttest and survey.  The pretest results were 0.974532.  The posttest results were 
0.418406285.  The 4 point Likert scale survey results were 0.658537.  According to these 
results, the posttest did not score well according to Cronbachs’ Alpha.  Better 
presentation of the information should be considered in the future.  
Chapter Summary 
 Chapter four delineated the statistical analysis of the pretest and posttest of the 
capstone project.  Overall, the learning objectives did show an increase in knowledge 
from the pretest to the posttest results.  Each of the four research questions focused on the 
diagnosis, co-morbidity, and treatment of the obese, PCOS patient. The quantitative data 
gathered displayed an increase in the posttest scores with two out of the four dimensions 
showing a statistical significance with a p value at <0.000001.  The findings of the study 
Mean Std. Deviation Std. Mean Error Lower Upper t df Sig. (2-tailed
Pair 1 Pretest-Posttest -0.3889 1.33456 0.31456 -1.0526 0.27477 -1.236 17 0.233
Pair 2 Pretest-Posttest -0.9444 0.93769 0.22099 -1.4107 -0.47819 -4.274 17 0.001
Pair 3 Pretest-Posttest -0.1111 1.02262 0.24103 -0.6197 0.39743 -0.461 17 0.651
Pair 4 Pretest-Posttest -2.5556 1.09664 0.25848 -3.1009 -2.01021 -9.887 17 0






did support the title being a paradigm shift in the diagnosis and treatment of PCOS.  
Continued education on recently updated guidelines in PCOS and obesity is warranted to 
continue dissemination of this knowledge in nursing.  Chapter V discusses the future 
recommendations for research along with limitations of the project and conclusions. 



















 This project provided nurse practitioners and nurse practitioner students the 
opportunity to receive an education offering on the recently released practice guidelines 
on obesity and the PCOS patient. The continuing education offering was designed 
utilizing an instrument to test knowledge gained in a pretest and posttest fashion. The 
research design allowed the ability to conclude whether a statistically significant analysis 
was positive after the presentation to increase the knowledge in this subject area.  The 
study focused on these four research questions: 
1.  Will the Continuing Education presentation on the new PCOS Guideline 
increase the knowledge base of the correlations between obesity and PCOS? 
2.  Will the Continuing Education presentation on the new PCOS Guideline 
increase the   knowledge base of diagnosing the patient with PCOS and 
obesity? 
3. Will the Continuing Education presentation on the new PCOS Guideline 
increase the knowledge base of inflammatory co-morbidities and PCOS? 
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4. Will the Continuing Education presentation on the new PCOS Guideline 
increase the provider’s knowledge of prescribing weight loss medications for 
the obese patient with PCOS? 
The nurse practitioner continuing education program was presented to a local 
group of nurse practitioners and nurse practitioner students.  A pretest and posttest was 
completed prior to and immediately following the educational offering. 
Limitations  
 The limitation of this project was the paradigm shift in how PCOS is diagnosed 
and treated in the obese population.  It was difficult to attempt to present this information 
on the inflammatory connections between PCOS and obesity rather than just focusing on 
the gynecological aspect of PCOS.  A second limitation involved having the information 
and results from a sample of convenience and would a different population setting 
produce similar results?  All participants were female (n=18).  A third limitation was the 
design of the instrument for this project.  Due to limited time in the presentation and 
utilization of the instrument, the validity was not able to be completed prior to the 
educational PowerPoint presentation.  This presentation was utilized for validation of the 
tool using a 4 point Likert scale survey.  These questions were developed by the primary 
investigator and not standardized.  All efforts were taken to validate the instrument for 
future educational opportunities. 
Two out of four dimensions of the pretest and posttest comparison were found to 
be statistically significant.  There needs to be better assimilation of education from the 
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PowerPoint for an increase in gained knowledge from the PowerPoint to increase 
statistical significance of test scores in all four dimensions. 
Future Research 
 Due to the updated practice guidelines for PCOS and obesity, this project allows 
for a change in the approach to treating PCOS. Research validates the need for education 
at the provider level in the pathophysiology of PCOS.  Even after the PowerPoint 
presentation, some questions continued to be answered incorrectly. 
In May, 2016, it was suggested that PCOS should have a name change of the 
condition to Metabolic Reproductive Disorder.  With representing a metabolic connection 
to the disease state, Nursing can begin to support this concept by educating and 
collaborating with other health care professions to assist in the positive outcomes in these 
women. 
Sustainability  
 The sustainability of this research involves the continued search for opportunities 
to disseminate the information in this capstone project.  With PCOS being the number 
one endocrine disorder in women, it is of great need for this approach with PCOS be 
supported.  Opportunities for educating the public and healthcare professionals will be 
pursued. Television programs along with journal articles will be pursued. 
Dissemination of Information 
 This project along with the statistical analysis of the increased knowledge in 
PCOS did find the need for more knowledge on this research in healthcare and the 
general public.  For the medical community, updated guidelines in PCOS and obesity will 
need to be taught in schools and continuing education programs.  For the public, allowing 
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a simple explanation of this research is needed to better understand the knowledge at a 
basic level.  Acceptance of this change in the approach to PCOS is important across the 
board. 
 This PowerPoint presentation is pending approval for one Continuing Education 
credit through American Academy of Nurse Practitioners organization.  This Continuing 
Education program has the potential to disseminate this knowledge across all forms of 
education pathways.  Another potential idea for dissemination of information would 
include a policy brief for state and national legislatures which would allow for 
government backing in funding opportunities and government support. 
Chapter Summary 
 This DNP Scholarly Project allowed for the participants to be given an 
opportunity to enjoy an Italian dinner along with a continuing education presentation 
regarding the updated guidelines for PCOS and obesity.  In addition, the continuing 
education program provide education regarding the inflammatory connections of PCOS 
and obesity.  Studies and current trends in PCOS reveal that updated education of current 
knowledge is lacking.  The research also reveals the misleading name as it relates to an 
ovarian problem rather than a metabolic, inflammatory etiology.  The research provided 
in this capstone project is vital to linking inflammation to PCOS and obesity in how the 
treatment of this disorder will be approached in the future.  The co-morbidities of PCOS 
and obesity have the potential to increase the risk of multiple inflammatory disease such 
as diabetes, heart disease, and cancer.  Primary care providers must be given the 
opportunity to continue understanding the paradigm shift in the diagnosis and treatment 
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A Paradigm Shift in the Diagnosis and Treatment of Polycystic Ovarian Syndrome:  
A Practice Change Index 
Four Dimensions 
 
I, ______________________, authorize my consent to complete the pre/posttest in order 
to identify areas of improvement for this presentation.  Recommendations will be written 
on the posttest.  
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APPENDIX B  
PRETEST/POSTTEST 
PCOS Index with Four Dimensions 
 
A. Will the Continuing Education presentation on the new guideline for PCOS 
increase the knowledge of the inflammatory correlations of obesity and 
PCOS? 
 
1. Elevated Tumor Necrosis Factor Alpha is an inflammatory marker that is not 
associated with? 
a. Obesity 
b. Polycystic Ovarian Syndrome 
c. Insulin Resistance 
d. Increased GLP-Production 
 
2. Only patients who have both Polycystic Ovarian Syndrome and obesity have 




3. Glucose intake alters Tumor Necrosis Factor Alpha in Polycystic Ovarian 
Syndrome and causes: 
a. A decrease in insulin 
b. An elevation in androgens 
c. A decrease in Luteinizing Hormone (LH) 
d. None of the above 
 
4. An elevation in Tumor Necrosis Factor Alpha decreases the production and 
increases the resistance of GLP-1 in PCOS.  This correlation also occurs in 
obesity.  This results in: 
a. Insulin Resistance 
b. Weight Gain 
c. Glucose Elevation 
d. All the Above 
 
 
B. Will the Continuing Education presentation on the new guideline for PCOS 
increase the provider’s knowledge base with diagnosing the patient with 




5. Current recommendations at the national American Diabetes Conference in 2016 
involving a name change of PCOS would be? 
a. Complex Metabolic Syndrome 
b. Metabolic Reproductive Syndrome 
c. Reproductive Metabolic Syndrome 
d. Androgen Reproductive Syndrome 
e. None of the above 
 
 
6. According to current practice guidelines for PCOS from the Endocrine Society, 
which guideline is recommended in diagnosing PCOS? 
a. Rotterdam criteria  
b. NIH criteria 
c. AE-PCOS Society criteria 
d. None of the above 
 
7. According to current practice guidelines for PCOS what screening measurements 
are assessed to screen for adiposity in PCOS? 
a. BMI 
b. Body Fat Composition 
c. Waist Circumference 
d. A and C 
 
8. According to current practice guidelines what lab testing should be routinely 
ordered     to diagnose patients with PCOS? 
a. Free Testosterone 




C. Will the Continuing Education presentation on the new PCOS guidelines 
increase the knowledge base of inflammatory co-morbidities and PCOS? 
 
9. What is not considered a co-morbidity associated with PCOS? 
a. Nonalcoholic fatty liver disease 
b. Diabetes 
c. Sleep apnea 
d. Pancreatitis 
 
10. According to the National Institute of Health, PCOS patients, with obesity have 
co-morbidities that worsen their disease state.  These include: 
 





d. All the Above 
 
11. Mental health conditions are a co-morbidity of PCOS? 
a. True 
b. False  
 
The following is a case study regarding co-morbidities in PCOS. 
“Jane Doe,” age 52 was recently released from the hospital with stage four uterine cancer 
after recently having both legs amputated from Insulin Dependent Diabetes Mellitus 
which is uncontrolled.  She decided to not undergo any intervention for her cancer except 
for her Total Abdominal Hysterectomy.  She tells the doctors and her family that she is 
just tired. 
 “I’m sorry family, friends, and health care providers.  I have attempted to find someone 
since I was in high school to noticing my:  missed periods, severe pelvic pain, weight 
gain, excessive hair, acne, insomnia, joint pain, edema, fatigue, episodes of rage, and low 
self-esteem.  I ended up on lots of antidepressants and occasional in-patient psychiatric 
hospitalizations.  But you know, they all said it was in my head.  I was so confused 
because I literally ate like a bird but continued to gain weight.  No one believed me.  My 
parents took me to many specialists and they did say that I had Polycystic ovarian 
syndrome. 
Years went by and I married and tried for years to have a baby.  I even attempted 
infertility drugs and that didn’t work.  We did in-vitro fertilization and after $50,000.00 I 
did have a girl.  I knew something was very wrong with me.  This time in my life was 
hell.  I was crazy most of the time.  I kept gaining weight, feeling even more reclusive.  I 
developed diabetes, hypertension, and fatty liver disease.  I was prescribed so much 
medicine.  And since I hated metformin, my health care provider started me on insulin.  
That is what fueled my downward slide. 
I kept gaining weight.   Over 300 pounds at that point, I had a heart attack.  Quadruple 
Bi-pass.  Next, a divorce.  My husband was done and told me that my health care 
providers said if I would just eat right and exercise that I would have been o.k.  I was on 
diets, ran 5ks, ate 500 calories, drank lemon/vinegar water, and even a gastric band.  I felt 
so defeated.   
My daughter was having the same problems and turned 18.  She went to her local health 
care provider who sent her to someone who specializes in PCOS.  She was 200 pounds, 
no periods, and excessive hair and acne.  This provider started her on weight loss 
medicine, spironolactone for hyper-androgenism, liraglutide, and a low-glycemic food 
plan.  In one year she lost 50 pounds, regained normal cycles, was sleeping, and 
developed a positive self- image. 
Recently that health care provider sat down with me and cried with me after my decision 
to not undergo any treatment for my cancer.  She told me if I would have been diagnosed 
and treated appropriately that I would probably have been a healthy and vibrant woman at 




12. When reading this case study, consistent symptoms and health problems being a 
co-morbidity     of PCOS, what appears to be the underlying issues that caused 




d. Health Care Providers 
 
D. Will the Continuing Education presentation on the new PCOS Guideline 
increase the provider’s knowledge of prescribing weight loss medications for 
the obese patient with PCOS? 
 
13. According to current 2013 Endocrine Society practice guidelines in 
PCOS___________ is recommended for weight loss in the PCOS patient who is 
overweight or obese? 
a. Metformin 




14. Which is not recommended in the treatment of obesity in PCOS according to the 
current 2013 Endocrine Society practice guidelines for PCOS? 
a. Liraglutide 
b. Exercise 
c. Diet control 
d. Reduced calories 
 
15. "PR" is a 41-year-old female who comes to the clinic for a new patient 
consultation. At today's visit, she is 5 feet 3 inches tall and 140 pounds. Her body 
mass index is 25. She is not worried about her weight.  She is more concerned 
with no menses and hair growth on her abdomen and back.  She has severe acne 
that bothers her self-esteem.  Only one pregnancy was induced by Clomid and 
weight loss. According to the 2016 AACE/ACE clinical practice guidelines for 









16. You obtain “PR’s” family history. Her mother and grandmother are both obese 
and have been diagnosed with type 2 diabetes and hypertension. Both had a 
difficult time getting pregnant.  They had severe issues with their cycles and 
losing weight.  There was no family history of thyroid cancer or pancreatitis.  Her 
previous history was free of those diagnoses as well. Her lab work showed 
elevated fasting insulin at 23, low B12 at 145, low Vitamin D at 17, HgbA1c of 
5.9%.  “PR” did not tolerate the Liraglutide, metformin, or orlistat.  After six 
months, she gained 30 pounds.  What is the next intervention after lifestyle and 
diet according to the 2016 AACE/ACE obesity guidelines?  
a. Phentermine 
b. Bontrix 
c. Roux-en-Y Gastric Bi-Pass 
d. Tradjenta 
 
Thank you for completing the pre/posttest! 
 
Recommendations for future presentations: 
